NYSE: ZBH

Zimmer Biomet (ZBH) Stock Analysis & Forecast

Nov 13 close

$103.21−1.35 (−1.3%)

Gekko Brief

AI summaryNov 9 close

This week brings a wave of product and strategic news from Zimmer Biomet. The company raised its 2026 sales growth and adjusted earnings outlook after third-quarter strength in hips, surgical specialties and technology offset continued softness in knees. It also outlined manufacturing changes, consolidating production in Warsaw and shifting some distribution to Indianapolis by the end of 2028, with roughly $60 million in exit costs expected from facility consolidation in Indiana, New Jersey and Switzerland. Separately, Zimmer Biomet introduced "Surgeon-Guided Autonomy," a new technology framework linking surgical planning, execution and recovery, and announced it will present at the Jefferies Global Healthcare Conference in London on 19 November.

ZBH closed at $108.33, up 2.6%, sitting above both its 50-day average of $95.27 and 200-day average of $92.14, with the 50-day above the 200-day. The GekkoIndex reads 44.4, placing the stock in the Distribution zone, down 11.2 over five readings. Despite the supportive trend, price remains 37.1% below Gekko Fair Value of $172.24.

The next earnings date is 9 February 2027, 91 days out and beyond a typical 20-day holding window. Smart money activity shows one Congressional buy and no sales over the past 90 days, alongside one unusual options signal in the past 30 days, with put premium of $670,000 and no call premium noted. Seasonality from this point has averaged a 4% gain over 20 trading days across 5 years, rising in 3 of them. Analyst consensus stands at 16 firms with 3 buy and 13 hold ratings, and a consensus target of $106.90.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

Zimmer Biomet price vs fair value

▲$168.83$103.21Nov ’25May ’26Nov ’26
Close $103.21200-day averageGekko Fair Value $168.83

Zimmer Biomet quick facts

Market cap
$19.53B
P/E ratio
26.1
Forward P/E
11.9
EPS, TTM
$3.96
Revenue, TTM
$8.57B
Profit margin
9%
Dividend yield
0.92%
Beta
0.47
Volume
2.52M avg 2.36M
1-year return
+14.6%
Typical daily move
±3.6%
Typical 20-day move
±4.8%
50-day average
$95.77
200-day average
$92.53
Next earnings
Feb 9 before open
Shares outstanding
189.3M
52-week range
$79.12$112.55

Zimmer Biomet swing-trade checklist

Zimmer Biomet scores 4 supportive, 2 mixed and 0 headwinds across the 6 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

4 supportive2 mixed0 headwinds

  • Trendsupportive

    Above 50 and 200-day

    Close $103.21 is above the 50-day ($95.77) and 200-day ($92.53) averages, and the 50-day is above the 200-day.

    See the chart
  • GekkoIndexmixed

    53.5, Neutral

    Reading 53.5 is in the Neutral zone.

    See the GekkoIndex
  • Fair valuesupportive

    38.9% below

    Price is 38.9% below Gekko Fair Value (more than 5% below).

    See fair value
  • Smart moneymixed

    Mixed

    Last 90 days: Congress 1 buy / 0 sales. Last 30 days: 1 unusual options signal.

    See smart money
  • Earnings risksupportive

    Reports in 86 days

    Next report Feb 9, 2027, 86 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitysupportive

    +3.3% on average

    From this point in the calendar, the next 20 trading days averaged +3.3% over 5 years, rising in 3 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Zimmer Biomet stock chart and price history

Zimmer Biomet closed at $103.21 on Nov 13, 2026, +14.6% over the past year, inside a 52-week range of $79.12 to $112.55.

Close50-day average200-day averageVolume
Zimmer Biomet share price, past year, with 50-day and 200-day moving averages and volume$80$90$100$110DecJan 2026FebMarAprMayJunJulAugSepOctNov103.21

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+9.4%
3 months
+5.1%
6 months
+23.3%
1 year
+14.6%
The full ZBH chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open ZBH in Gekko

Follow Zimmer Biomet through every session

Put ZBH on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track ZBH in GekkoFree for 7 days. No credit card required.

About Zimmer Biomet

Zimmer Biomet develops, produces, and sells devices used in orthopedic reconstruction, the kind of surgery that repairs or replaces joints. Alongside these core products, it makes items for sports medicine, biologics, extremities and trauma care, spine and craniomaxillofacial and thoracic treatment, dental implants, office-based technology, and other surgical tools, serving hospitals and medical practices that rely on these products in patient care.

The business is structured around three geographic segments. The Americas segment covers the United States along with other markets across North, Central, and South America. The Europe, Middle East and Africa segment includes countries such as France, Germany, Italy, Spain, and the United Kingdom. The Asia Pacific segment spans markets including Japan, China, Australia, New Zealand, Korea, Taiwan, India, Thailand, Singapore, Hong Kong, and Malaysia.

Zimmer Biomet traces its founding to Justin O. Zimmer in 1927 and keeps its headquarters in Warsaw, Indiana. Its shares are listed on the NYSE under the ticker ZBH.

Listed
NYSE
Sector
Health technology
Industry
Medical specialties
Website
zimmerbiomet.com

Zimmer Biomet GekkoIndex: the smart money zone

Zimmer Biomet’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 53.5, in the Neutral zone, up 8.3 points over five sessions.

010053.5Neutral

Up 8.3 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying46+1.2%+1.3%+1.1%+0.8%
Accumulation296+0.5%+1.0%+1.3%+0.5%
Neutral (current zone)347−0.7%−1.2%−2.0%−3.6%
Distribution12−0.6%−3.3%−7.6%−14.7%
Selling1Too few readings yet

Average ZBH share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the ZBH price, zone by zone.Track ZBH in Gekko

Is Zimmer Biomet stock overvalued? Gekko Fair Value

Zimmer Biomet trades 38.9% below Gekko Fair Value of $168.83, so the shares are undervalued on Gekko’s estimate.

Gekko’s own estimate of what Zimmer Biomet shares are worth, recalculated every trading day.

$168.83

Gekko Fair Value, Nov 14, 2026

38.9% Undervalued

At the end of Aug 2026 the price was 2.8% below the estimate.

Gekko Fair ValueShare price, month end
$169$103Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open ZBH in Gekko

Zimmer Biomet insider and Congress trading

No open-market insider purchases were filed for Zimmer Biomet, and members of Congress disclosed 1 purchase and 0 sales, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for ZBH in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every ZBH insider filing, plotted on the chart in Gekko.Open ZBH in Gekko

Congress trades last 90 days

1trade disclosed: 1 purchase and 0 sales.

MemberTypeAmountDisclosed
Ro Khanna
House, CA, purchase
Purchase$1,001 - $15,000Oct 9
traded Sep 11

From congressional disclosures, which report amounts as ranges.

Buybacks

Zimmer Biomet has been buying back its own shares.

Bought back, quarter ended Sep 30, 2026
$78.50M
As a share of market cap
0.40%
Trailing four quarters
$829.3M

From company filings.

Unusual options activity last 30 days

1signal, 0% of the flagged premium in calls.

Latest: Bearish flow on Oct 15, $670K in unusual premium.

Hedge funds and billionaires quarter ended Jun 30

1of the funds Gekko tracks holds ZBH.

0added1opened0trimmed1sold out
Every signal with its contract, strike and premium, and which funds are on each side.Unlock in Gekko

Zimmer Biomet earnings: next date and track record

Zimmer Biomet reports on Feb 9, 2027, before the open (86 days away), and beat the EPS estimate in 7 of its last 8 reports.

7 of 8reports beat the EPS estimate
±8%average move across the report
4 of 8reports followed by a gain

Share-price move across each report

+2.9%Oct ’24−6.8%Feb ’25−9.9%May ’25+8.9%Aug ’25−14.2%Nov ’25+6.6%Feb ’26−13.5%Apr ’26+1.4%Aug ’26

Last earnings call, Aug 5, 2026 AI summary

What they said
Zimmer Biomet reported Q2 2026 net sales of $2.177 billion, up 4.8% reported and 4% organic constant currency, beating expectations. U.S. organic growth was 4.6%; international 3.1%. Hips grew 5.1% CC with Z1 stem exceeding 40% U.S. share. Technology & Data/Bone Cement/Surgical surged 21.5% with record capital sales. S.E.T. accelerated 180bps sequentially; Knees were essentially flat at 0.1% CC.
Guidance
Management upgraded full-year 2026 outlook following Q2 outperformance. Growth drivers include iodine-coated hip expansion in Japan, accelerating OrthoGrid adoption, ROSA Shoulder launch, and continued U.S. sales force transformation momentum expected to improve performance in H2 2026.
ReportedEPSSurpriseRevenueSurpriseMove
Aug 5, 2026$2.07
est $2.01
+3.0%$2.18B
est $2.13B
+2.0%+1.4%
Apr 28, 2026$2.09
est $1.86
+12.2%$2.09B
est $2.07B
+0.8%−13.5%
Feb 10, 2026$2.42
est $2.40
+0.9%$2.24B
est $2.22B
+0.9%+6.6%
Nov 5, 2025$1.90
est $1.88
+1.1%$2.00B
est $2.01B
−0.5%−14.2%
Aug 7, 2025$2.07
est $1.98
+4.5%$2.08B
est $2.06B
+1.0%+8.9%
May 5, 2025$1.81
est $1.77
+2.3%$1.91B
est $1.90B
+0.7%−9.9%
Feb 6, 2025$2.31
est $2.29
+0.9%$2.02B
est $2.01B
+0.4%−6.8%
Oct 30, 2024$1.74
est $1.74
0.0%$1.82B
est $1.80B
+1.4%+2.9%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Zimmer Biomet stock forecast and analyst price targets

Analysts’ average 12-month price target for Zimmer Biomet is $116.24, +12.6% from the last close, from 16 firms rating the stock in the last 90 days.

$116.24consensus 12-month target, +12.6% from the last close
Low $97High $130
Buy3
Hold13
Sell0

Each firm’s latest rating in the last 90 days: 16 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 9BarclaysHold, maintained$115+11.4%
Nov 9Piper SandlerHold, maintained$110+6.6%
Nov 5UBSBuy, reiterated$130+26.0%
Nov 5Truist FinancialHold, maintained$114+10.5%
Nov 5J.P. MorganHold, maintained$120+16.3%
−2.0%average 20-day move after past Neutral readings
+3.3%average move over the next 20 trading days in the last 5 years
±3.6%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Zimmer Biomet seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Zimmer Biomet averaged +3.3% across the last 5 years, rising in 3 of them.

Next 20 trading days, by year

−6.0%2021+13.3%2022+9.1%2023−1.9%2024+2.8%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days+1.4%3 of 5
Next 10 trading days+1.8%4 of 5
Next 15 trading days+3.0%3 of 5
Next 20 trading days+3.3%3 of 5
Next 30 trading days+3.9%3 of 5

For scale, ZBH’s typical 20-trading-day move in either direction is about 4.8%.

Zimmer Biomet market cap and key statistics

Zimmer Biomet’s market cap is $19.53B, with a P/E ratio of 26.1 and revenue of $8.57B over the last twelve months.

Valuation

Market cap
$19.53B
P/E ratio
26.1
Forward P/E
11.9
EPS, TTM
$3.96
Gekko Fair Value
$168.83

Trading

Volume
2.52M
Avg volume, 20 days
2.36M
52-week high
$112.55
52-week low
$79.12
Shares outstanding
189.3M

Financials

Revenue, TTM
$8.57B
Profit margin
9%
Return on equity
6%
Quarterly earnings growth, YoY
−13.8%

Risk and income

Beta
0.47
Typical daily move
±3.6%
Typical 20-day move
±4.8%
Dividend yield
0.92%

Zimmer Biomet stock news this week

Coverage of Zimmer Biomet this week reads positive: 5 positive, 3 neutral and 0 negative headlines.

News sentiment positive

Zimmer Biomet peers

Zimmer Biomet’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
TMOThermo Fisher Scientific−0.2%Neutral15.0% above
ABTAbbott Laboratories+0.3%Neutral10.5% below
DHRDanaher0.0%Neutral4.7% above
ISRGIntuitive Surgical0.0%Neutral17.5% above
MDTMedtronic+0.7%Neutral14.2% below
SYKStryker−2.0%Neutral0.1% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Medical specialties

Zimmer Biomet stock FAQ

What is Zimmer Biomet’s market cap?

Zimmer Biomet’s market cap is $19.53B at the Nov 13, 2026 close of $103.21, with 189.3M shares outstanding. The shares trade on a P/E ratio of 26.1.

What is the Zimmer Biomet stock forecast?

The consensus analyst 12-month price target for Zimmer Biomet is $116.24, +12.6% from the last close. Of the 16 firms that rated the stock in the last 90 days, 3 rate it a buy, 13 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Zimmer Biomet stock overvalued or undervalued?

On Gekko’s estimate Zimmer Biomet is undervalued: the Nov 13, 2026 close of $103.21 is 38.9% below Gekko Fair Value of $168.83. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Zimmer Biomet report earnings next?

Zimmer Biomet is expected to report on Feb 9, 2027, before the market opens (86 days away). Analysts expect earnings of $2.49 per share on revenue of $2.29B. Zimmer Biomet beat the earnings estimate in 7 of its last 8 reports, moving 8% on average across the report.

What is Zimmer Biomet’s 52-week high and low?

Zimmer Biomet’s 52-week high is $112.55 and its 52-week low is $79.12; it closed at $103.21 on Nov 13, 2026, +14.6% over the past year. Over the last five years the shares peaked at $149.25 on May 2, 2023.

Is Zimmer Biomet stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (trend, fair value, earnings risk and seasonality), 2 as mixed (gekkoindex and smart money). The checklist is a description of current data, not a recommendation.

Is there unusual options activity in Zimmer Biomet?

Gekko flagged 1 unusual options signal in Zimmer Biomet over the last 30 days, with $0 of flagged premium in calls and $670K in puts. The latest, bearish flow, was on Oct 15, 2026 with $670K in unusual premium. The signal-by-signal table is in Gekko.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Zimmer Biomet the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.